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Abstract
Millions of peoples in the world suffer from their bone damage tissues by disease or 
trauma. Every day, thousands of surgical procedures are performed to replace or repair 
these tissues. The availability of these tissues is a big problem, and their costs are expen-
sive. The repair of these defects has become a major clinical and socioeconomic need with 
the increase of aging population and social development. The emerge of tissue engineering 
(TE) is considered as a glimmer of hope to contribute in solving this problem. It aims at the 
regeneration of damaged tissues with restoring and maintaining the function of human 
bone tissues using the combination of cell biology, materials science, and engineering prin-
ciples. In this chapter, the current state of the tissue engineering in particular bioceramic 
scaffolds was discussed. Concept of tissue engineering was explored. Bioceramic scaffold 
materials, their processing techniques, challenges taken into consideration the design of 
the scaffolds, and their in-vitro and in-vivo studies were highlighted. The scaffolds with 
extra-functionalities such as drug release ability and clinical applications were mentioned.
Keywords: bioceramics, scaffolds, classifications, processing, in-vivo, in-vitro, 
applications, challenges
1. Introduction
Bone defects and its functional disturbance have become a huge health care problem in the 
worldwide [1, 2]. The repair of these defects has become a major clinical and socioeconomic 
need with the increase of aging population and social development [3, 4]. Every day, thousands 
of surgical procedures are performed to replace or repair tissue that has been damaged through 
disease or trauma. The availability of these tissues is a big problem and their cost is expensive. 
The emerge of tissue engineering (TE) is considered as a glimmer of hope to contribute in solv-
ing this problem. It aims to regenerate damaged tissues. Through this approach, the regenera-
tion of damaged tissue is achieved by combining cells from the human body with highly porous 
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biomaterial scaffolds. These biomaterials scaffolds are metal, polymer, or ceramics which act 
as templates for growing the new viable tissues [5]. The suggested materials for tissue engi-
neering (scaffolds) must interact with cells and culture media from the in-vitro stage to their 
implantation. They have to (i) host a sufficient amount of cells and (ii) support their viability 
for several weeks. Like any implanted biomaterials, there are some characteristics that must be 
found in the ideal scaffolds such as: (1) they are porous structure to allow cell penetration, tissue 
in-growth, (2) biocompatible, i.e., compatible without causing any toxic reactions or an inflam-
matory response, (3) bioactive, i.e., form strong bonding with the host bone, (4) has sufficient 
mechanical properties. A major difficulty in the design of scaffolds is to simultaneously tailor 
these requirements due to their competing nature in fulfilling host tissue demands. Namely, 
if a specific requisite is achieved, another one is negatively affected. It can be said, although 
some scaffolds have a highly porous structure with interconnected pores and have features 
like degradability, biocompatibility, and bioactivity, they cannot be used under a heavy load 
because of their poor mechanical properties. Thus, the biomaterials scaffolds with suitable 
mechanical properties, bioactivity, biocompatibility, and biodegradability in order to become 
the bottleneck. Therefore, recently many researchers have tried to find new solutions that tackle 
this bottleneck for achieving abovementioned requirements. They have tried to achieve that 
through many ways for example, (i) proposing new biomaterials like bioceramics, or com-
posite based bioceramics (bioceramic-polymers composites, or bioceramic metal composites), 
(ii) using new processing techniques or developing the current processing techniques [6–9].
To verify the bone job of TE tissue engineering in restoring and maintaining the function of 
human bone tissues using the combination of cell biology, materials science, and engineering 
principles, the scaffolds must have the following criteria:
Biocompatibility: The biocompatibility of the scaffolds means that their ability to perform as the 
3D substrates that will have surface chemistry (with the facilitation of molecular and mechanical 
signaling system) to promote cell adhesion, proliferation, and migration in vitro [10]. And after 
implantation, the scaffold must not induce any undesirable immune reaction that may reduce 
healing or cause rejection by the body [11].
Biodegradability: The gradual degradation of scaffolds helps to make space for new grow-
ing tissues to deposit their own matrix and hence avoids the necessity of second surgery to 
remove the implant [12]. Thus, it is one of the crucial factors for scaffolds. The degradation 
of an ideal scaffold must occur with time in-vivo, and its rate must proportional to the rate of 
the tissue formation. The biodegradation products should be nontoxic to other tissues in-vivo.
Bioactivity: Stimulation of rapid tissue attachment to the implant surface (without formation 
of fibrous tissue) and creation of a stable long-term bonding that prevents micromotion at the 
interface and the onset of an inflammatory response [13].
Structural requirements: An ideal scaffold should have void volume for vascularization, neo 
tissue formation and remodeling, necessary to facilitate host tissue integration on implanta-
tion [14]. Biomaterials should be processed to provide a highly porous structure with inter-
connected porosity for transporting oxygen, nutrients, and waste metabolites in and out of 
the scaffold without significantly compromising the mechanical stability of the scaffold [14]. If 
a scaffold has too small pore size, it may enact the cells to penetrate the scaffold initially and 
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subsequently to migrate through these pores to the other regions of the scaffolds. But, if it has 
too large pore size, it may inhibit the effective neo-tissue regeneration by disabling the cells to 
bridge pores during cell proliferation [13].
Manufacturing technology/commercialization potential: The fabrication technique of the scaf-
folds is a crucial factor in the production of TE scaffolds. It is a challenge to produce a large quan-
tity of scaffolds at a relatively low or reasonable cost, i.e., to be easily offered to the market [13, 14].
This chapter defines the current state of tissue engineering regarding bioceramic scaffolds. In 
addition, the complexity of this field. In other words, the following items will be highlighted 
in details:
It discusses
• Concept of tissue engineering
• Bioceramic scaffold materials
• Processing techniques
• Challenges
• In vitro and in vivo studies of bioceramic scaffold materials
• Scaffolds with extra-functionalities such as drug release ability
• Clinical applications
2. Concept of tissue engineering
Over 8 million surgical operations for treating the organ failure or tissue loss are performed annu-
ally in the US [15]. Despite of the success made by the organ transplantation and reconstruction 
surgery in the life quality, and in some cases the life save, there are still problems associated with 
the patients. These operations, in most cases, need either organ donation from donor individual 
or tissue transplantation from a second surgical site in the individual being treated. The gener-
ated problems from the use of organ transplantation are the drastic shortage of donor organs. For 
example, in 1996, 20,000 donor organs were only available, and the number of patients waiting 
the organs were 50,000. This means that patients are more likely to die while they are waiting for 
a human donor than in the first 2 years after transplantation [15]. The problems associated with 
the second surgical sites are pain and morbidity. Accordingly, organs development, tissues, and 
synthetic materials outside of the body ready for future transplant use have emerged [5, 15–21]. 
The estimated market of these products is approximately $5 billion worldwide [16].
Tissue engineering may be defined as the application of biological, chemical, and engineering 
principles toward the repair, restoration, or regeneration of living tissue by using biomaterials, 
cells, and growth factors alone or in combination. In the early 1990s, the emerged tissue engi-
neering started to address the limitations of tissue grafting and alloplastic tissue repair. The con-
cept was to transplant a biofactor like cells, genes and/or proteins within a porous degradable 
material known as a scaffold. The biofactors are used to stimulate tissue repair. They include 
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Figure 1. Tissue engineering triad [11].
stem cells and gene therapy approaches. The tissue/organ repair has been considered the ulti-
mate goal of surgery from ancient times until now. Generally, repair is achieved through two 
approaches: (i) tissue grafting and organ transplantation and (ii) alloplastic or synthetic mate-
rial replacement. Since 2000 BC gold has been used in cranial defects as repair; however, the 
grafting of the tissue has been used at the earlier of 1660s. Both approaches mentioned above 
have limitations. The grafting needs second surgical sites with associated morbidity and is con-
fined by finite amounts of material, especially for organ replacement. One of the efforts made to 
solve the problems associated with the use of the autologous allograft, and bone cements is the 
finding appropriate materials to replace lost or missing tissues from the human body [22, 23].
The definition of ‘Tissue Engineering’ term according to the NSF workshop held in 1988 is “the 
application of principles and methods of engineering and life sciences toward the fundamen-
tal understanding of structure-function relationships in normal and pathological mammalian 
tissues and the development of biological substitutes to restore, maintain, or improve tissue 
function” [24]. This definition hold some promises such as (1) driving out the re-operations by 
using biodegradable biological substitutes, (2) encourage the use of biological substitutes as a 
natural regeneration process to repair or replace lost or damaged tissues i.e. to provide long 
term solutions, (3) solving the generated problems from the immune rejection of implants, 
infections or diseases transmission pertinent allografts and xenografts, and organ donation 
shortage, (4) offering practical solutions for currently untreatable cases [25, 26].
Since emergence of tissue engineering in the mid-1980s, it has continued to evolve as an 
exciting and multidisciplinary field that aiming to develop biological substitutes to restore, 
replace, or regenerate defective tissues. Key component of tissue engineering are cells, scaf-
folds, and growth-stimulating signals which are generally referred to as the tissue engineer-
ing triad (Figure 1) [27]. Porous 3D scaffolds are generally seeded with cells and occasionally 
with signaling molecules or subjected to biophysical stimuli in the form of a bioreactor [28]. 
These cell-seeded scaffolds are either subjected to a pre-implantation differentiation culture 
in-vitro to synthesize tissues and then transplanted or are directly implanted into the injured 
site, using the body’s own systems, where tissue regeneration is induced in-vivo [11]. These 
approaches with porous scaffolds are shown in below by Figure 2 [29].
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3. Bioceramic scaffold materials
Today, tissue engineering has emerged as a rapidly expanding approach to overcome the 
drawbacks of the classical treatments by regenerating damaged tissues, instead of replac-
ing them [11, 30]. This approach leads to the development of biomaterials to prepare porous 
3D scaffolds as biological substitutes to restore, maintain, or improve defective tissues [14]. 
Various materials have been proposed for tissue engineering including different types of bio-
materials (metal, polymers, and ceramics) to overcome the problems associated with natural 
bone grafts in reconstructive surgery. Although porous metallic scaffolds are considered as 
the most suitable implants for hard tissue engineering in load bearing areas, they have some 
limitations such as (1) lacking of biological recognition or bioactivity [31, 32], (2) lacking of 
the integration of biomolecules [33], (3) nonbiodegradable [33], (4) releasing of toxic ions [33], 
(5) corrosion or wear, and (6) The architecture control [34]. One of the essential requirements 
for using a biocompatible metal in tissue engineering scaffold is the surface modification by 
coating with bioactive ceramic materials, where it reduces some of the limitations of metallic 
scaffolds.
Another primary materials studied mostly to fabricate scaffolds are polymers such as poly-
lactic acid [35, 36], polyglycolic acid [37], polyurethane [38], and a number of copolymers [39–
41]. Natural polymer-based scaffolds have excellent bioactivity, biodegradability but poor 
mechanical properties. These characteristics reveal their successful use in soft tissue engineer-
ing and limit their use in the load bearing applications. Moreover, there is still immunological 
concern associated with naturally derived polymers. An additional problem limits the appli-
cation of the natural polymeric materials scaffolds, there are still a question mark on their 
structure homogeneity and reproducibility [11, 35–37, 42–48]. Metal and polymer drawbacks 
Figure 2. Tissue engineering approaches with porous scaffolds [30].
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mentioned above lead to emerging of a new type of materials prevent the production of the 
wear debris and can be designed to more closely match the material properties of natural 
bone. Such materials must be mechanically stronger than polymers and play a critical role in 
providing mechanical stability to construct prior to synthesis of new bone matrix by cells. The 
materials nominated to fit this purpose are called bioceramics.
Ceramic scaffold possesses many aspects like being bioactive, biocompatible, biodegrad-
able, mechanically stiff (Young’s modulus) [49], less elastic and brittle. They also exhibit 
shaping difficulties. Bioceramics can be classified into three groups as given in the following 
Table 1 [50]: 
Later group (3) is used in bone tissue engineering, various calcium phosphates (CaPs) spe-
cially HA, β-TCP, and biphasic calcium phosphate, BCP (mixture of HA and β-TCP) has long 
been studied as porous scaffold materials. As natural bone composed of large amounts of HA 
(Ca
10
(PO
4
)
6
(OH)
2
), so it might be useful to use HA, β-TCP as they closely simulate the chemi-
cal and crystalline nature of the mineral phase of the native bone [51, 52], and hence, they 
will be biocompatible. Hydroxyapatite (HA) is known by its bioactivity, biocompatibility, 
nontoxicity, noninflammatory, osteoconductivity, and biodegradability. By its comparison 
with β-TCP, it degrades slowly in following order: OCP > α-TCP > β-TCP > u-HA> > s-HA [53] 
and after implantation, it undergoes little conversion to a bone like material [54]. For the same 
porosity, β-TCP scaffolds often exhibit lower mechanical strength than HA scaffolds, limiting 
their use in the load bearing applications [55]. The degradation rate and other properties can 
be influenced by varying HA to β-TCP ratios in BCP. Interestingly, researchers have shown 
that dopant addition in the scaffolds of CaPs can control the biocompatibility, densification 
behavior, dissolution rates, and mechanical strength [33, 56].
Recently, calcium phosphates containing materials used for tissue engineering are nominated 
as bioactive glasses, silicate bioactive glasses, borate bioactive glasses, phosphate bioactive 
glasses, and akermanite. Each one will be explained as the following:
Bioactive glasses have already shown their excellence as promising biomaterials for tissue 
engineering due to their ability to enhance bone cell growth, bonding to both hard and soft 
tissues [27], ability to restore defect sites and controllable degradation rate in vivo. Glass com-
positions and of the scaffolds and their microstructure play an important role in the determi-
nation of the degradation rate and conversion to an HA-like material, mechanical properties, 
and response to cells.
Groups Phases
1. Bioinert e.g., Aluminum oxide (Al
2
O
3
) and zirconium oxide (ZrO
2
).
2. Surface bioactive e.g., Sintered hydroxyapatite(s-HA) at high temperature, bioglass
3. Bioresorbable e.g., Sintered hydroxyapatite(u-HA) at low temperature, tricalcium phosphate (α-TCP and 
β-TCP), tetracalcium phosphate (TTCP), octacalcium phosphate (OCP).
Table 1. Bioceramics classification.
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Recently, doped bioglasses with various elements, such as Cu, Zn, and Sr, promote the healthy 
bone growth that have been developed [58]. These types of the bioglass showed an enhance-
ment of angiogenesis (formation of blood vessels) [55, 59] and soft tissue wound healing [55]. 
And this capacity of bioglasses has provided an alternative approach to the use of expensive 
growth factors for stimulating neovascularization of engineered tissues [55].
45S5 glass has long been established as highly bioactive, biocompatible [60], and biodegrad-
able. The composition of 45S5 glass is 45% SiO
2
, 6% P
2
O
5
, 24.5% CaO, 24.5% Na
2
O and the low 
SiO
2
 content (<55% SiO
2
), high content of network modifiers like Na
2
O and CaO, high CaO/
P
2
O
5
 ratio contributes to the bioactivity of 45S5 glass. The immersion of this form of glass is 
body fluid, and it forms HCA layer (carbonate substituted HA, typical bone composition) 
on its surface that significantly promotes osteoblast activity. However, there is a difficulty 
in the processing of this glass into a porous 3D scaffold due to its low mechanical strength, 
slow degradation rate, and conversion to an HA mineral [52]. Recently, it was found that by 
heating this type of glass to high temperatures (>950°C), its phases crystallize with strong 
mechanical strength and become bioactive glasses. In addition, it converts to a biodegradable, 
amorphous calcium phosphate at the body temperature, and in a biological environment [61]. 
This process enables the mechanical competence and biodegradability to be incorporated in a 
single scaffold, making it promising as tissue engineering scaffold [51].
Borate bioactive glass: Researchers have indicated that borate or borosilicate bioactive glasses 
promote cell proliferation and differentiation in vitro, as well as tissue infiltration in vivo [55]. 
Borate bioactive glasses degrade as faster as than 45S5 glasses. They completely convert to an 
HA-like material because of their lower chemical stability [62]. The degradation rate can be 
controlled by manipulating the glass composition [62, 63]. Besides, there is a concern about 
the toxicity of boron released into the solution as borate ions (BO
3
)
3
 [55].
Phosphate Bioactive glass: [55] It forms networks, where CaO and Na
2
O act as network modifi-
ers. It shows a chemical affinity toward bone due to the existed ions in the organic mineral phase 
of the bone. The degradability of this glass can be controlled by modifying their composition. Its 
flexibility displayed has made it potential resorbable biomaterials for tissue engineering.
Akermanite (Ca
2
MgSi
2
O
7
): Recently, it has received more attention due to its controllable 
mechanical properties and degradation rate [64, 65]. In previous studies, marrow-derived 
or adipose-derived stem cells and osteoblasts have displayed good activities of proliferation 
and osteogenesis on akermanite compared by β-TCP [66–70]. The recent studies suggest that 
this Mg-containing silicate ceramic as a bone graft material may meet the requirement of 
bone regeneration than b-TCP. However, the mechanism of akermanite’s bioactivity is still 
unknown. The materials chemistry of biomaterials is one of the main factors in the proliferation 
and differentiation of various cells.
In tissue engineering, biomaterials play a critical role. They act as a 3D template, supply 
mechanical support and allow artificial extracellular matrix environment (ECM) for neo-
tissue formation. This means that one type of biomaterials is not sufficient to compromise 
hard and soft tissue engineering. Therefore, each type from the biomaterial types such as 
metals, ceramics, and polymers has its own importance in making tissue engineering scaf-
folds. Therefore, the composite materials have been emerged. Sometimes biocompatibility 
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and biodegradability of ceramics are not sufficient. Moreover, ceramics are very brittle, and 
too stiff, while the polymers are found to be biocompatible and biodegradable with low 
mechanical strength. So, this biological and mechanical mismatch can be overcome by blend-
ing the ceramics with natural or synthetic polymers or metal. Recently, various composites 
were explored such as synthetic polymers/natural polymers, synthetic polymers/bioceramics, 
polymers/metals, metals/ceramics, …etc. However, novel metal/polymer/ceramic composites 
have also been suggested for load bearing applications [34]. Composite materials are neces-
sary approach to obtain optimal biological, structural, mechanical, and chemical properties of 
scaffolds. Thus, bioceramics/polymers are commonly used composites.
Finally, needless to say, yet, there exists no polymers or metals that can effectively bond to 
bone. On the other hand, it does not exist ceramic materials that can sufficiently in mechanical 
properties. Therefore, composites of biodegradable polymers and hard metals with bioactive 
ceramic composites are still a promising approach.
4. Processing techniques
It is a key point to obtain porous structure with proper mechanical properties to create a micro-
environment for cell adhesion and proliferation. Nature bone has multi-level 3D pore structure 
size ranging from several nano to hundreds of micrometers [71]. This level of pore sizes meets 
the requirements of a tissue growth. Pore sizes in the range of 150–800 μm prevent the growth 
of the bone tissue and the vessels of the blood. However, pore sizes in the range of 10–100 μm 
are useful for the growth of the blood capillaries, nutrients exchange, and waste products 
excretion. Nano pores are larger specific surface area and more active targets. They are good 
for the formation of apatite and the attachment of protein or osteoblast [72]. Meanwhile, they 
are also important for the adjustment of cell adhesion and proliferates.
Many fabrication techniques are available to produce ceramic scaffolds with varying architec-
tural features. There are two main types of fabrication techniques: conventional techniques 
and advanced techniques. Conventional techniques for the fabrication of porous structure 
mainly include replica; sacrificial template; and direct foaming as seen in Figure 3 [3].
Figure 3. Calcium phosphate–based scaffold (Willis [57]).
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The replica technique employs a synthetic or natural template that is impregnated with a 
ceramic suspension. After drying, the template is removed thus creating a replica of the origi-
nal template structure [73]. Many synthetic and natural cellular structures can be used as 
templates to fabricate macroporous ceramics through the replica technique [74].
The sacrificial template method incorporates some sort of pore former or sacrificial material 
to act as a place holder within the ceramic powder or slurry. Once the green body is formed, 
the pore former is removed to leave behind pores which are empty (Figure 1(b)) [73]. This 
method leads to porous materials displaying a negative replica of the original sacrificial tem-
plate, as opposed to the positive morphology obtained from the replica technique described 
above [74].
Direct foaming is a process where gas bubbles are incorporated into a ceramic suspension, and 
once the slurry is set and dried, the ceramic retains the resulting spherical pores (Figure 4(c)) 
[73]. To obtain high-strength ceramic foams, the dried objects are then sintered at high tempera-
tures. The total porosity of the obtained foam is proportional to the amount of gas incorporated 
into the suspension or liquid medium during the foaming process. The sizes of the pores depend 
on the stability of the wet foam before setting [74].
Freeze casting is considered as one of the promising techniques for manufacturing of porous 
structure. It utilizes growing ice crystals in a ceramic slurry to form the pores in a ceramic 
Figure 4. Scheme of possible processing routes used for the production of macroporous ceramics [77].
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Figure 5. Freeze cast process for bioceramic preparation [78].
body. It is a simple technique to produce porous complex-shaped ceramic or polymeric parts. 
It has first been developed as a near net shape forming technique, yielding dense ceramics 
parts with fine replicate of the mold details. In this technique, a ceramic suspension is poured 
into a mold and then frozen. The frozen solvent acts as a temporary binder to hold the part 
together, see Figure 5. The de-molded part is subjected to freeze drying to sublimate the 
frozen solvent under vacuum, avoiding the stresses and shrinkage that might lead to cracks 
and warping during normal drying. After drying, the parts are sintered to obtain a scaffold 
with (1) a complex and often anisotropic porous microstructure and (2) proper strength and 
stiffness. By controlling the direction of ice crystals growth direction, it is possible to tailor a 
preferential orientation for the porosity in the ultimate products [75].
Human cortical bone has a compressive strength of 100–150 MPa and toughness of 2–12 MPa m1/2, 
while human trabecular bone has a compressive strength of 2–12 MPa and toughness of 0.1–
0.8 MPa m1/2. The question is: How can design ceramic scaffolds and mimic the structure and 
properties of natural bone as closely as possible? This means the scaffold fabrication must be 
carried out with high accuracy taking into consideration the effective and functional proper-
ties such as the microstructure, mechanical properties as well as the biocompatibility [73].
In some cases, it is difficult to achieve the targeted pore for tissue growth such as intercon-
nectivity, pore size, and pore geometry when traditional processing techniques are used. The 
limited control over the pore characteristics generates closed pores and leads to lack of inter-
connecting pores. In addition, it gives low strength and variable properties. Recently, additive 
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manufacturing (AM) techniques, the rapid prototyping (RP) and electrospinning, have been 
proposed for the fabrication of porous ceramic scaffolds. They have several potential benefits 
over traditional techniques [73].
The rapid prototyping (RP) techniques: RP techniques are referred to as a solid free-form 
(SFF) manufacturing. They are precise and reproducible for controlling the internal pore size, 
porosity, pore interconnectivity, mechanical performance, and overall dimensions of tissue 
engineering scaffolds [76, 77]. Based on programmed 3D images, they are defined as auto-
mated deposition of each tomographic layer sequence into the desired architecture through 
an additive layer-by-layer method [78]. One of the main requirements for translational appli-
cations is a high productivity using automated method and possibility to produce patient-
specific constructs; therefore, an RP-based method can potentially be used to fabricate such 
customized tissues [79]. The benefits of RP technology are numerous, e.g. the versatility of 
modeling software allows for the fabrication of the desired parts without the need for expen-
sive molds, and the process is usually achieved in only a few steps. It could easily be used 
in the manufacturing bio-scaffolds with fit needs of a specific individual and match the sur-
rounding bone which may vary from person to another depending on the age, health, condi-
tion of the surrounding bone, or location within the intended recipient, see Figure 6 [73].
The most relevant RP techniques in the design of 3D scaffolds for tissue engineering are 3D 
printing (3DP), selective laser sintering (SLS), stereolithography (SLA), robocasting (RC), and 
Figure 6. Main RP-based techniques relevant for tissue engineering applications [93].
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Figure 7. Schematic of a typical electrospinning system.
fused deposition modeling (FDM). Figure 6 shows a schematic diagram of the processing of 
each RP based-technique [80].
3D printing (3DP): The inkjet head of this device prints droplets of a binder fluid onto a pow-
der bed. This process is repeated for every layer until the 3D scaffold structure is printed, 
and the remaining powder is removed. It has been used to create scaffolds for use in bone 
tissue engineering. One of the important benefits of this method is the powder bed sup-
port by itself for each successive layer. The fragility of the obtained parts is considered a 
drawback [81–88].
Selective laser sintering (SLS): It is a heat dependent. This method uses a CO
2
 laser beam to 
selectively sinter polymer or composite powders to form material layers. The laser beam is 
directed onto the powder bed by a high precision laser scanning system [89].
Stereolithography (SLA): This technique is light dependent. The laser beam selectively initi-
ates solidification in a thin layer of liquid photopolymer [90].
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Robocasting (RC): This technique is slurry dependent. It consists of the robotic deposition of 
a highly concentrated colloidal suspension (inks) [91, 92].
Electrospinning: This technique is easy to use. It is used to produce nano to microfibers by 
subjection of a solution of polymeric materials or ceramic/polymeric composites to an electric 
field. Solid fibers are produced from electrified jets using high voltage. These fibers are con-
tinuously elongated because of the electrostatic repulsion between the surface charges and 
the solvent evaporation, see Figure 7 [94].
This technique allows obtaining high surface area scaffolds, which simulate the size scale of 
fibrous proteins found in the natural ECM [95–97]. One of the great interests in this methodol-
ogy is the capacity to easily produce materials at the biological length scale for tissue engineer-
ing and drug delivery applications [98]. Also, this technique is able to form nonwoven fibrous 
mats, which ensure fiber production from a broad range of precursor materials including syn-
thetic polymers, natural polymers, semiconductors, ceramics, or their combinations [99, 100]. As 
mentioned above, the strength and the great merit of electrospinning technology are the ability 
to conduct fiber size, porosity, and shape using processing variables, such as applied voltage, 
polymer melt flow rate, capillary/collector distance, polymer/ceramic concentration, and solvent 
conductivity and volatility [94]. Figure 7 displays schematic of a typical electrospinning system.
Recently, inorganic nanoparticles, such as HA, bioactive glass, and carbon nanotubes, have been 
widely co-electrospun into polymer nano fibers to enhance their mechanical properties and their 
biocompatibility response [101–106]. Although the bioceramic needle oriented in polymer fiber 
is challenging, but it is very important for enhancing the mechanical properties of the scaffolds.
5. Challenges
The design and fabrication of the synthetic tissue scaffold and the engineering of tissue con-
structs in vitro and in vivo are big challenges. Various materials like metals, ceramics, natu-
ral and synthetic polymers, and even their composites have been explored as TE scaffolds. 
Bioceramics and polymers are suitable for bone TE, where the native bone composed mainly 
of a naturally occurring polymer and biological apatite. Since ceramics are brittle and the 
mechanical properties of the polymers are not sufficient, the applications of these materials are 
limited, in particular, in load-bearing areas. Although metals have high mechanical strength 
are suitable for load-bearing applications, but they are bio-inert and their biodegradability are 
none. Therefore, they are not suitable for soft tissue engineering. Generally, the most impor-
tant challenge of tissue engineering is to mimic what happens in nature. Attempts are being 
made to engineer in vitro practically every tissue and organ in the body [11]. In addition, the 
following items are playing an important role in the properties of the bioceramic scaffolds:
(1) Macrostructure: It is important to determine the geometry of the regenerating tissue and 
in turns to be capable to re-shape it.
(2) Mechanical properties: the scaffolds should have sufficient mechanical strength to provide 
temporary function in a defect until the tissue regenerates. If the mechanical properties 
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of the native bone are used as a guideline in the scaffolds designing, they must exhibit 
linear elastic properties with a moduli of hundreds of megapascals and microstructures 
of preferred orientations due to bone anisotropy. In addition, it is important to know that 
the scaffold mechanical properties will decrease with the scaffold degradation. Thus, if the 
scaffolds have sufficient mechanical properties at the time of implantation, the change of 
their mechanical properties during the degradation could be expected and affected on the 
function within the tissue defect [107, 108].
(3) Pore size, porosity and interconnectivity: The pore size is an important variable to stimu-
late cell ingrowth and new bone formation [109, 110], while the interconnected porous 
network and porosity are critical in maintaining spatially uniform cell distribution, cell 
survival, proliferation, and migration in vitro. Moreover, the scaffold’s porosity (exceed-
ing 60%) and degree of pore interconnectivity directly affects the diffusion of physiologi-
cal nutrients and gases [111, 112]. Interestingly, the pores with smaller sizes than 1 μm are 
appropriate to interact with proteins and are mainly responsible for inducing the forma-
tion of an apatite-like layer in contact with simulated blood fluids. Pores of sizes from 1 to 
20 μm are important in cellular development, where the cells are attached and the orienta-
tion and directionality of cellular in-growth. Pore of sizes between 100 and 1000 μm are 
essential to assure nutrient supply, waste removal of cells and promoting the in-growth 
of bone cells. Finally, the presence of pores of sizes >1000 μm will play an important role 
in the implant functionality [113, 114].
6. In-vitro and in-vivo studies of bioceramic scaffolds
The in-vitro and in-vivo responses of bioceramic scaffolds are dependent on their composi-
tion and their pore architecture (microstructure). Various studies were handled biological 
response of the bioceramic scaffolds, some of them discussed below.
6.1. In-vitro and in-vivo studies of bioactive glass scaffolds
The ability of bioactive glass scaffolds to support cell proliferation and function in-vitro and 
tissue ingrowth in-vivo has been shown in numerous studies [115–122]. Fu et al. showed that 
13–93 bioactive glass scaffolds prepared using a polymer foam by replica method supported 
the attachment and proliferation of MC3T3-E1 preosteoblastic cells both on the surface and 
within the interior pores of the scaffold [115].
Poh et al. prepared and estimated the in-vitro response of two different types of bioactive glass 
composite scaffolds. They are polycaprolactone with 45S5 glass (PCL/45S5) and strontium-
substituted glass with polycaprolactone (PCL/SrBG). These two types of bioactive glasses 
were incorporated into polycaprolactone (PCL) and fabricated by additive manufacturing 
technology. The in vitro results showed that the rates of degradation of these scaffolds were 
PCL/SrBG > PCL/45S5 > PCL scaffolds. It was found that the degradation rate of PCL/SrBG 
scaffolds was faster than PCL/45S5 scaffolds. This is due to the substitution of Sr2+ of larger 
ionic radius (1.12A°) by Ca2+ of lower ionic radius (0.99 A°) leading to the expansion of the 
silicate glass network [7, 35, 36]. Such expansion weakens the glass network and increases the 
Scaffolds in Tissue Engineering - Materials, Technologies and Clinical Applications62
dissolution rates of the SrBG. The cytotoxicity test indicated that all scaffolds (PCL, PCL/45S5, 
and PCL/SrBG) were noncytotoxic and are able to support cell attachment, growth, and pro-
liferation; at day 7 and 14, PCL/SrBG (control and osteo group) show a significantly higher 
degree of mineralization compared to all other groups (PCL/45S5 and PCL); indicating that 
PCL/SrBG can stimulate earlier matrix mineralization [123]. Melchers et al. investigated the 
effect of alumina from 0.5 to 15 mol% in mesoporous bioactive glasses based on composition 
80% SiO
2
–15%CaO -5% P
2
O
5
. Sol–gel method in combination with a structure directing agent 
for the formation of mesopores was used. It was found that the incorporation of Al
2
O
3
 in a 
range of 1 to 10 mol% reduces the order of the mesostructure, while the further increase of 
doped amount of Al
2
O
3
 to 15 mol% creates well-ordered mesopores again. In addition, pore 
diameter, pore volume, and specific surface area decrease only slightly on the incorporation 
of Al
2
O
3
. In-vitro bioactivity tests of these glasses, a decrease in their bioactivities upon the 
incorporation of small amounts of alumina was observed, while a sudden drop was noticed 
beyond the addition of 3 mol% of Al
2
O
3
. These results back to the strong interaction of Al3+ 
and PO
4
3−, which could be proven by multinuclear single and double resonance solid state 
nuclear magnetic resonance (NMR) spectroscopy [124].
6.2. In-vitro and in-vivo studies of hydroxyapatite scaffolds
Generally, hydroxyapatite (HA) is a material which most often induces osteogenesis both 
in-vivo and in-vitro. Adding HA to other materials (either natural or synthetic) could, there-
fore, modulate the osteogenic potential and mechanical properties of the subsequent mixture. 
Therefore, many papers have been devoted for a combinatorial approach of HA with another 
supporting material [45]. The choice of supporting material is often paramount. The main 
reasons of combination of HA with another material are improved strength, increased poros-
ity, altered cell binding abilities, and so forth. These materials are divided to natural materials 
and synthetic materials. Natural materials (collagen, gelatin, fibrinogen) tend to have good 
cellular adhesion remodeling properties but can also carry a high risk of immune response. 
On the other hand, synthetic materials, however, are less immunogenic and more custom-
izable but carry higher risks of toxicity. Furthermore, MSCs can be included in such scaf-
folds for differentiation to osteogenic lineages and/or implantation for bone defects purposes, 
although differentiation media are often required. Therefore, HA scaffolds containing MSCs 
can be used as a combinatorial modality for treating bone disease and degeneration. The com-
bining of stem cells, in particular, MSCs, into the various HA-based scaffolds increases the 
scaffolds potential use for bone regeneration. Adding the benefits of MSCs immunomodula-
tory, immune inert, and immune-privileged state to a synthetically or naturally enhanced HA 
scaffold has demonstrated superior results than the scaffolds alone [125].
In another study, porous chitosan/hydroxyapatite (C/HA) scaffolds were fabricated via freeze-
drying with desired pore size. The in-vitro proliferation of Human osteoblasts (hOBs) on 
the scaffolds were evaluated. Then, these scaffolds were combined with the adenoviral vec-
tor encoding vascular endothelial growth factor and green fluorescence protein (Ad-VEGF). 
In-vivo studies were conducted by subcutaneously implanting inactivated and gene-activated 
C/HA sponges containing hOBs into the epigastric fasciovascular flaps of Wistar rats. The 
results show that, in the in-vitro investigation, the adenovirus encoding VEGF gene-activated 
macroporous C/HA composite scaffold supports transfection of human primary osteoblasts 
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and bone-like tissue formation. In-vivo findings demonstrate that C/HA + AdVEGF + hOBs 
promote abundant neovascularization during ectopic bone formation, while viral gene ther-
apy has some drawbacks. Generally, all findings support the notion that gene-activated C/HA 
scaffold could have potential in vascularized bone tissue engineering [126].
Campos et al. studied the synthesis of three-dimensional (3D) scaffolds composed of 50 wt.%HA 
and 50 wt.% collagen for bone tissue engineering. Self-assembly method with a 0.125% glutar-
aldehyde solution as cross-linked was used a synthetic route. The in-vitro evaluations are cyto-
toxicity using MC3T3 cells, proliferation and differentiation. Proliferation and differentiation 
were tested using STRO-1A human stromal cells for time up to 21 days. The results show that no 
cytotoxicity was observed in the scaffold by MC3T3 cells. STRO-1A cells were found to adhere, 
proliferate, and differentiate on the 3-D scaffold, but limited cell penetration was observed [127].
Porous composite bioceramics of hydroxyapatite and dicalcium phosphate dehydrate (HAp/
DCPD) were prepared using polyurethane foam. They were designed for application in osteo-
conductive and osteoinductive scaffolds. In-vitro and in-vivo examinations were performed to 
evaluate the biological responses of the prepared porous composites. In-vitro studies were per-
formed by immersion of the samples in SBF. The in-vivo test was conducted by inserted porous 
composite samples into defects in the medial femoral condyle of rabbits. From in vitro and in-
vivo studies, it can be concluded that the scaffolds are biocompatible without inflammation. After 
implementation, necroses or rejection of the tissue was noticed. The application success of the 
combined HAp and DCPD scaffolds for generating a new bone tissue is attributed to the merge 
of the biocompatibility property and the formation ability of a favorable 3D matrix for human 
osteoblast cells to adhere and spread, taking into consideration the advantage of TCP osteoinduc-
tion to the superior bioactivity and osteoconduction of HAp. Finally, the prepared scaffolds seem 
to be a promising biomaterial for low-weight-bearing orthopedic applications [128, 129].
The obtained data from literature indicate that biphasic calcium phosphate is the optimal 
cell-supporting material. Biphasic calcium phosphate should be recommended as the most 
suitable matrix for osteogenic cells expansion and differentiation in tissue engineered systems 
[130]. I.E. biphasic calcium phosphate (BCP) ceramics composed of HA and ß-TCP with vary-
ing HA/ß-TCP ratios have been extensively studied in the past two decades, because they 
combine the excellent biocompatibility and bioactivity of HA and a degradation rate of ß-TCP 
that matches the growth rate of newly formed bon.
6.3. In-vitro and in-vivo studies of calcium phosphate cement (CPC) scaffolds
It has been reported by Kent et al. in vitro and in vivo measurements of commercial calcium 
phosphate cement is considerably stronger in vivo compared to in vitro, the cause of this attrib-
uted to bone formation within the cement pores and a high degree of osseointegration [131].
Chen et al., 2013 proved that when hUCMSCs and hBMSCs were seeded onto a CPC scaffold. 
Then, they implanted into the defects, new bone formation increased with time. Compared 
with CPC control without cells, 88% and 57% increases in new bone were achieved when 
hBMSCs and hUCMSCs were seeded with CPC, respectively (see Figure 8) [132]. These 
results confirmed by Zeng et al., 2012, whereas he found when h-BMSCs seeding with CPC, 
the greater new bone was generated greater than in a model without cells in a rabbit maxillary 
sinus floor elevation model [133].
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7. Scaffolds with extra-functionalities such as drug release ability
Scaffolds are implants or injects, which are used to deliver cells, drugs, and genes into the 
body. Scaffold matrices can be used to achieve drug delivery with high loading and efficiency 
to specific sites. This means that the scaffolds must be designed to provide not only the struc-
ture integrity required for bone regeneration but also for controlling dose of drug release.
Figure 8. Bone regeneration in critical-sized cranial defects in nude rats with 3 groups (CPC control without cells; CPC 
with hUCMSCs; CPC with hBMSCs).
Bioceramic Scaffolds
http://dx.doi.org/10.5772/intechopen.70194
65
Zhao et al. designed and prepared porous scaffold, which composed of a newly designed 
polylactone, poly(e-caprolactone)-block-poly(lactic-co-glycolic acid) (b-PLGC) copolymer, 
and β-tricalcium phosphate (β-TCP). Then, this scaffold was loaded with an antituberculous 
drug (rifampicin, RFP) to cure serious bone tuberculosis from two points of views (bone regen-
eration and antituberculous drug therapy). The in-vitro drug release experiment showed that 
hydrophobic RFP could be released from the b-PLGC/TCP scaffold in a sustained manner 
for 84 days. Accordingly, RFP concentrations obtained in blood and tissues surrounding the 
implant could reach a high value in 12 weeks, which was above the effective level needed for 
the treatment of tuberculosis. The cytological assay proved that the RFP-loaded scaffold has 
a good cell cytocompatibility. In another trial, it was found that the composite system gave a 
good regeneration ability for bone. Therefore, the b-PLGC/TCP scaffold can perform a local 
long-term drug release as well as osteogenesis capability. These achievements are suitable for 
clinical applications [134].
In another study, Zhu et al. proved that a mesoporous silica nanoparticulate/β-TCP/bioactive 
glass (BG) composite drug delivery system for osteoarticular tuberculosis therapy much higher 
antituberculous drugs (rifampicin (INH) and isoniazid (RFP)) loading capacities than pure 
β-TCP scaffold. The best concentrations of drugs (INH and RFP) for treating tuberculosis (TB) 
in-vivo can be maintained for an extra-long duration over 42 days without significant long-
term lesions to liver and kidney [135].
It has been reported by Kundu et al. that HAp exhibited better drug release than β-TCP when 
CFS (ceftriaxone sodium and sulbactum sodium in 2:1 w/w ratio) drug was used. HAp and 
pure β-TCP based porous scaffolds were prepared by applying together starch consolidation 
and foaming techniques. A bilayered coating was also applied to the pore surfaces of some 
samples using chitosan and b-lactamase–cephalosporin derivative to assess their effect on 
sustained drug releasing. The result of bilayered coating of chitosan with CFS provided pro-
longed release pattern for more than 5 weeks irrespective of the scaffold material, a period 
that is considered to be sufficient for local drug delivery to combat osteomyelitis [136].
8. Clinical applications
Ceramics include a broad range of inorganic and non-metallic compounds. Although their 
applications in tissue engineering is recent, they demonstrate good results, whatever they 
are a single phase or composite. Herein, we will explored the clinical application of the most 
common examples of bioceramic (HA, TCP, BCP, and bioactive glasses) that are used as in 
tissue engineering applications.
Hydroxyapatite: By insertion porous HA wedges into the tibias of ten knees in seven patients 
having high tibial osteotomies, it was found that pores located at the interface, at the time of 
hardware removal, were completely filled with bone, and the bone depth formed increased 
consistently with time [137]. In another study, the transverse sections of porous HA implants 
placed in rabbit tibias demonstrated a new bone growth through the pores. After 8 weeks, a 
formed concentric lamellae by osteon structure was observed around a single vessel in the 
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pores of sizes 50 and 100 μm of the cylindrical HA implants. Also, similar structures were dis-
played around the multiple vessels in the pores of sizes 300 and 500 μm of the implants [114]. 
The examination of 103 patients suffering from cranial defects in which Bone SourceTM was 
used, a success rate of 97% was recorded [138]. Such high record was achieved by the implant 
maintenance for 24 months.
Tricalcium phosphate (TCP): TCP has become one of the first calcium phosphates to be used 
in bioceramics for bone substitution and repair. Thanks to its stability at high temperature 
and ease of processing as tricalcium phosphate–based ceramics 339 ceramics. β-TCP contain-
ing ceramics are one of the major bioresorbable synthetic bone that used daily by orthopedic 
surgeons and dentists. They are used in the form of porous ceramic pieces and granules to 
reconstruct all kinds of bone defects, from augmentation of alveolar ridge defects after a tooth 
extraction and before implant positioning to sinus reconstruction correction of various defor-
mities and bone reconstruction following injury or disease. Recently, α-TCP has also been 
proposed as ceramic materials for similar applications [139].
Tricalcium phosphate/hydroxyapatite biphasic ceramics (BCP): The BCP concept is based 
on an optimum balance between the more stable phase (HA) and the more soluble phase 
(β-TCP). BCP bioceramics of various sizes and shapes are used in maxillofacial surgery, den-
tistry, ear, nose and throat (ENT) surgeries, and orthopedics. For example, BCP granules with 
HA/TCP of 60/40 were placed in the alveolar cavity immediately after tooth extraction and 
followed up radiographically from 0 to 5 years [140].
Bioactive glasses: Bioactive glasses have a wide range of clinical applications in both medi-
cine and dentistry. It is used as bone graft material, a coating materials, and disinfectants.
As bone graft material: Bioglass has been used clinically as a synthetic bone graft material for 
over 10 years under two different product names: Novabone_ for orthopedics and Perioglass 
for maxillofacial surgery. The first reported clinical application of bioactive glass was the 
treatment of conductive hearing loss for the reconstruction of the bony ossicular chain of the 
middle ear.
As a coating materials: More researchers use bioactive glasses as a coating materials for den-
tal implants. Bioactive silicate glass has also been used for implant coatings, as a bone graft, 
in dentifrices, and as air-abrasive particles to remove carious enamel and dentin. Goudouri 
et al. indicated that bioactive glass could be used as a dental material to improve the bonding 
of the restorative material to dentin [139].
As disinfectants: Bioactive glasses can serve as topical endodontic disinfectants with no effects 
on dentin stability. Bioactive glass can raise the pH of an aqueous environment to produce its 
antimicrobial effects. For example, when implanted in areas of periodontal defects, Bioglass 
can inhibit bacterial colonization at the surgical site by increasing the pH and calcium levels.
As a bone regeneration: Bioactive glass can promote bone regeneration, with osteostimulatory 
effects in vitro. Similarly, in primate models, bioactive glass filled bony defects by stimulating 
osteoproduction. Felipe et al. reported that bioactive glass particles were able to treat periodon-
tal defects and triggered the development of mineralized bone in dogs [141, 142].
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9. Conclusion
This chapter discussed the bioceramic scaffolds which considered as one-third of the tissue 
engineering triad. It dealt with the most effective materials that were used in the bioceramic 
scaffolds. All traditional and advanced techniques for scaffolds manufacturing, their require-
ments, and challenges taken into consideration the design of the scaffolds were explored. In 
additions, several examples of the most common bioceramic scaffolds were highlighted from 
different corners, e.g., their testing in in-vitro and in-vivo, their extra functionalities such as 
drug release ability and their clinical applications.
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